0.82
1.23%
0.010
アフターアワーズ:
.80
-0.02
-2.44%
Assertio Holdings Inc (ASRT) 最新ニュース
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Update - MarketBeat
Investors in Assertio Holdings (NASDAQ:ASRT) have unfortunately lost 87% over the last five years - Yahoo Finance
Assertio Holdings faces Nasdaq delisting over share price rule - MSN
Assertio Holdings, Inc. (NASDAQ:ASRT) Sees Significant Decrease in Short Interest - MarketBeat
Jane Street Group LLC Sells 277,889 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) - Defense World
Geode Capital Management LLC Purchases 42,750 Shares of Assertio Holdings, Inc. (NASDAQ:ASRT) - Defense World
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Assertio Holdings Names New Chief Commercial Officer, Awards Major Stock Incentive Package - StockTitan
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of Illinois against Assertio Holdings, Inc. - AccessWire
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Up 14.1% in December - MarketBeat
Is Assertio Holdings (NASDAQ:ASRT) A Risky Investment? - Simply Wall St
Assertio appoints new independent director to board By Investing.com - Investing.com South Africa
Assertio appoints new independent director to board - Investing.com
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors - The Manila Times
Assertio Holdings Taps Former Astellas President Who Led $5B Sales Growth to Join Board - StockTitan
Assertio’s (ASRT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Assertio Therapeutics shares get buy rating on clinical trial results By Investing.com - Investing.com Canada
Assertio (NASDAQ:ASRT) Receives Buy Rating from HC Wainwright - MarketBeat
Assertio Holdings, Inc. (NASDAQ:ASRT) Short Interest Down 11.5% in November - MarketBeat
Assertio reports positive Rolvedon trial results for breast cancer By Investing.com - Investing.com Australia
Assertio Announces Results of Rolvedon (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study - Marketscreener.com
Assertio reports positive Rolvedon trial results for breast cancer - Investing.com
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study - The Manila Times
Assertio's Rolvedon Shows Promising Clinical Data in Breast Cancer Trial with Same-Day Chemo Dosing - StockTitan
Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO - The Manila Times
Assertio Holdings Creates Transformation Office, Appoints New Leadership to Drive Growth Strategy - StockTitan
Assertio Holdings Inc (NASDAQ: ASRT): Blank Check On Growth? - Stocks Register
Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer - GlobeNewswire Inc.
Beam Therapeutics names Sravan K. Emany as new CFO - Investing.com
HC Wainwright Forecasts Stronger Earnings for Assertio - MarketBeat
Assertio shares hold price target, buy rating on stable Indocin share By Investing.com - Investing.com Canada
Assertio Holdings, Inc. (NASDAQ:ASRT) Shares Acquired by Empowered Funds LLC - Defense World
Assertio Holdings Q3 2024 Earnings Preview - MSN
Assertio stock gains amid Q3 earnings, clash with activist investor - MSN
Insider Buying: Assertio Holdings, Inc. (NASDAQ:ASRT) Director Acquires $60,000.00 in Stock - MarketBeat
Assertio Holdings director Heather Mason buys $60,000 in shares By Investing.com - Investing.com Nigeria
Assertio Holdings director Heather Mason buys $60,000 in shares - Investing.com
Assertio Holdings CEO Brendan O'Grady buys $9,950 in common stock - Investing.com India
Spectrum Pharma Faces Senate Probe Call Over Alleged Rolvedon Data Fraud | ASRT Stock News - StockTitan
Assertio Holdings Inc (ASRT) Quarterly 10-Q Report - Quartz
Assertio Holdings Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Call Transcript - Insider Monkey
Assertio: Q3 Earnings Snapshot - The Washington Post
Assertio Therapeutics’ Q3 2024 Earnings Overview - TipRanks
Assertio stock gains amid Q3 earnings, clash with activist investor (NASDAQ:ASRT) - Seeking Alpha
Assertio (ASRT) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Assertio Reports Third Quarter 2024 Financial Results - The Manila Times
Assertio Holdings, Inc. Announces Board Changes - Marketscreener.com
大文字化:
|
ボリューム (24 時間):